{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T18:15:24Z","timestamp":1770488124836,"version":"3.49.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2017.11.008","type":"journal-article","created":{"date-parts":[[2017,11,12]],"date-time":"2017-11-12T15:00:20Z","timestamp":1510498820000},"page":"591-598","source":"Crossref","is-referenced-by-count":23,"title":["Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies"],"prefix":"10.1016","volume":"24","author":[{"given":"C.","family":"Rodrigo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Weeratunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.D.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Rajapakse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.11.008_bib1","first-page":"98","article-title":"Recent developments and future prospects in the treatment of visceral leishmaniasis","volume":"3","author":"Sundar","year":"2016","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/00034983.1998.11813337","article-title":"Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B\u2013lipid complex","volume":"92","author":"Sundar","year":"1998","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.cmi.2017.11.008_bib3","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2017.11.008_bib4","series-title":"Review manager 5.1 [computer programme]","author":"Nordic Cochrane Centre","year":"2011"},{"key":"10.1016\/j.cmi.2017.11.008_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2017.11.008_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1590\/0037-8682-0455-2016","article-title":"Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil","volume":"50","author":"Borges","year":"2017","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.cmi.2017.11.008_bib7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00002030-199906180-00009","article-title":"Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group","volume":"13","author":"Laguna","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2017.11.008_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2017.11.008_bib9","doi-asserted-by":"crossref","first-page":"e2613","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial","volume":"8","author":"Khalil","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib10","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.cmi.2017.11.008_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.11.008_bib13","doi-asserted-by":"crossref","first-page":"e3169","DOI":"10.1371\/journal.pntd.0003169","article-title":"Efficacy and safety of amphotericin B emulsion versus liposomal formulation in Indian patients with visceral leishmaniasis: a randomized, open-label study","volume":"8","author":"Sundar","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0924-8579(00)00312-5","article-title":"A\u00a0single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study","volume":"17","author":"Thakur","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2017.11.008_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1179\/000349804225003154","article-title":"A\u00a0comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis","volume":"98","author":"Thakur","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.cmi.2017.11.008_bib16","first-page":"259","article-title":"Comparison of regimens of amphotericin B deoxycholate in kala-azar","volume":"103","author":"Thakur","year":"1996","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.cmi.2017.11.008_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0035-9203(96)90271-0","article-title":"Comparison of three treatment regimens with liposomal amphotericin B (Ambisome) for visceral leishmaniasis in India: a randomized dose-finding study","volume":"90","author":"Thakur","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.cmi.2017.11.008_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","volume":"323","author":"Sundar","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2017.11.008_bib19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4269\/ajtmh.2002.66.143","article-title":"Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study","volume":"66","author":"Sundar","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2017.11.008_bib20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4269\/ajtmh.14-0259","article-title":"Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral leishmaniasis: a phase 2 study","volume":"92","author":"Sundar","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2017.11.008_bib21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0035-9203(99)90036-6","article-title":"Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis","volume":"93","author":"Bodhe","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.cmi.2017.11.008_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000764","article-title":"A\u00a0curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy","volume":"4","author":"Mondal","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4269\/ajtmh.14-0657","article-title":"Short-course treatment regimen of Indian visceral leishmaniasis with an Indian liposomal amphotericin B preparation (Fungisome)","volume":"94","author":"Goswami","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2017.11.008_bib24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/377542","article-title":"Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study","volume":"37","author":"Sundar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-127-2-199707150-00007","article-title":"Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony","volume":"127","author":"Sundar","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2017.11.008_bib26","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.11.008_bib27","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/00034983.1999.11813462","article-title":"Oral treatment of visceral leishmaniasis with miltefosine","volume":"93","author":"Sundar","year":"1999","journal-title":"Ann Trop Med Parasitol"},{"key":"10.1016\/j.cmi.2017.11.008_bib28","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2017.11.008_bib29","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2017.11.008_bib30","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF02763048","article-title":"Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study","volume":"73","author":"Singh","year":"2006","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.cmi.2017.11.008_bib31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib32","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2017.11.008_bib33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(10)62050-8","article-title":"Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial","volume":"377","author":"Sundar","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2017.11.008_bib34","first-page":"117","article-title":"A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India","volume":"5","author":"Das","year":"2009","journal-title":"Ther Clin Risk Manage"},{"key":"10.1016\/j.cmi.2017.11.008_bib35","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4269\/ajtmh.2011.10-0409","article-title":"Pharmacokinetics of oral sitamaquine taken with or without food and safety and efficacy for treatment of visceral leishmaniais: a randomized study in Bihar, India","volume":"84","author":"Sundar","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.cmi.2017.11.008_bib36","series-title":"Control of visceral leishmaniasis","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.cmi.2017.11.008_bib37","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.11.008_bib38","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-3156.2009.02306.x","article-title":"Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India","volume":"14","author":"Olliaro","year":"2009","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.cmi.2017.11.008_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000818","article-title":"Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent","volume":"4","author":"Meheus","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(05)70296-6","article-title":"Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980\u20132004","volume":"5","author":"Olliaro","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib41","doi-asserted-by":"crossref","first-page":"e0005781","DOI":"10.1371\/journal.pntd.0005781","article-title":"Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: a first step to assess the feasibility of establishing an individual patient data sharing platform","volume":"11","author":"Bush","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib42","first-page":"779","article-title":"A\u00a0randomized comparison of classical mode of administration of amphotericin B with its newer modes of administration in kala-azar","volume":"46","author":"Thakur","year":"1998","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.cmi.2017.11.008_bib43","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/520665","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions","volume":"45","author":"Sundar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2017.11.008_bib44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/tropej\/fmp132","article-title":"Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day\u2014a randomized trial","volume":"56","author":"Singh","year":"2010","journal-title":"J\u00a0Trop Pediatr"},{"key":"10.1016\/j.cmi.2017.11.008_bib45","first-page":"186","article-title":"Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis","volume":"47","author":"Sundar","year":"1999","journal-title":"J\u00a0Assoc Physicians India"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17306389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17306389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:35:09Z","timestamp":1559352909000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17306389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1198743X17306389"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.11.008","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}